James C. Yao, MD, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
An overview of the data and rationale that led to the approval of nivolumab and pembrolizumab for NSCLC, with an emphasis on specific patient populations likely to benefit from this approach and future directions for clinical research in this area.
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
James R. Berenson, MD, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
Xgeva (denosumab) has received approval from the US Food and Drug Administration (FDA) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy, and the agent was granted Orphan Drug Designation.
As a first step toward developing quantitative models, investigators recently developed a mathematical framework to simulate the systemic dissemination of T cells activated in response to focal therapy.
Since the identification of the role of the JAK kinase family in the late 1980s, awareness of this has grown significantly. These tyrosine<br /> kinases have been proven to transmit a variety of signals into the cells with many biological consequences, adding to the interest in the targetability of the JAK pathway. However, better understanding of the complexities of JAK signaling are being evaluated in clinical trials.
Although chemotherapy remains the standard treatment for small cell lung cancer in first- and second-line settings, notable progress in immunotherapies have recently taken place, begging the question of how these agents will be optimized in this tumor type.
The SURPASS-ET trial demonstrated ropeginterferon alfa-2b's superior efficacy over anagrelide, achieving higher durable response rates and greater reduction in JAK2 allele burden among patients with essential thrombocythemia.
Patients with PD-L1-positive non-small cell lung cancer that has metastasized to the brain did better with cemiplimab plus chemotherapy than with investigator's choice of chemotherapy.
Discover the most anticipated abstracts at the 67th ASH Annual Meeting and Exposition, showcasing groundbreaking research in hematologic malignancies and innovative treatments.
Jeffrey J. Raizer, MD, provides an overview of a study that analyzed the overall survival and toxicity profile of proton therapy for large-volume re-irradiation for patients with recurrent glioma.
Jennifer E. Amengual, MD, discusses the study she presented at the 2013 American Society of Hematology (ASH) Annual Meeting. The trial analyzed dual targeting with the HDAC inhibitor ACY-1215 and bortezomib in preclinical models of lymphoma.
This past year, 2020, will go down as a practice-changing one for the treatment of esophageal cancer, said Yelena Y. Janjigian, MD.
Progress in the development of chimeric antigen receptor T-cell therapy and other cell-based therapies has led to new therapeutic options for advanced malignancies. CAR T-cell agents approved by the FDA in recent years include axicabtagene ciloleucel for diffuse large B-cell lymphoma and tisagenlecleucel for both DLBCL and acute lymphoblastic leukemia.
Despite the widespread prevalence of hepatocellular carcinoma (HCC), effective treatment options for both primary and secondary liver tumors have remained elusive, as these tumors are difficult to manage, especially in cases where the tumor is unresectable.
Jennifer H. Kuo, MD, director, Thyroid Biopsy Program, Columbia University, discusses a study looking at the incidence of thyroid cancer among breast cancer survivors.
Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Acquired resistance to tyrosine kinase inhibitors targeting <em>EGFR</em> mutations in patients with non–small cell lung cancer are leading to next-generation therapies equipped to circumvent the mutations that arise from initial treatment. A review of these mechanisms, and the latest agents being developed to address them, shows that the pipeline holds promise for the future.
Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus.
The monoclonal antibody cirmtuzumab, currently in clinical trials to treat CLL, targets ROR1 on the surface of cancerous B cells, and the agent may have a wider reach in the treatment of ovarian and other cancers.